24/7 Patient Assistance: 760-405-8205

Monica M. Mita, MD

Medical Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated Asbestosis Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma

  • Bio & Insurance Information

    Dr. Monica Mita is a specialist in medical oncology in Los Angeles, California and she is working in collaboration with many regional hospitals, such as Cedars-Sinai Medical Center and UCLA Medical Center Santa Monica. She got his diploma from Carol Davila University of Medicine and Pharmacy. She did a fellowship in hematology/oncology at University of Texas Health Science Center. The doctor has been practicing for more than 20 years.

  • Education & Training


    Carol Davila University of Medicine and Pharmacy

    Medical School


    University of Texas Health Science Center


  • Board Certifications

    American Board of Internal Medicine - Hematology

    American Board of Internal Medicine - Oncology

  • Hospital & Practice

    Cedars-Sinai Medical Center

    Languages: English/Spanish

    (310) 423-3277

    8700 Beverly Blvd

    Los Angeles, California 90048

    Read More

    UCLA Medical Center, Santa Monica

    Languages: English/Spanish

    (424) 259-6000

    1250 16th St

    Santa Monica, California 90404

    Read More
  • Publications & Memberships

    Dr. Monica M. Mita has contributed to 3 publications.

    Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity.

    Gong, J.,Sachdev, E.,Mita, A. C.,Mita, M. M.; World J Methodol. 1900 Jan 01.

    See more >>

    Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer.

    Sarantopoulos, J.,Mita, M. M.,Birrer, M. J.,Cranmer, L. D.,Campos, L. T.,Zhang, X.,Bristow, P.,Kaito, H.,Strout, V.,Camacho, L. H.; Target Oncol. 2015 Oct 29.

    See more >>

    Targeting survivin inhibits renal cell carcinoma progression and enhances the activity of temsirolimus.

    Carew, J. S.,Espitia, C. M.,Zhao, W.,Mita, M. M.,Mita, A. C.,Nawrocki, S. T.; Mol. Cancer Ther.. 2015 Mar 27.

    See more >>


    American Society of Clinical Oncology